First National Trust Co Has $359,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

First National Trust Co trimmed its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,487 shares of the medical instruments supplier’s stock after selling 71 shares during the period. First National Trust Co’s holdings in Becton, Dickinson and Company were worth $359,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the third quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $33,000. Tompkins Financial Corp increased its position in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the period. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Opal Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the second quarter valued at $45,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.0 %

NYSE BDX opened at $231.26 on Thursday. The stock’s 50 day simple moving average is $236.66 and its 200 day simple moving average is $235.13. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $249.89. The firm has a market cap of $66.84 billion, a PE ratio of 38.93, a price-to-earnings-growth ratio of 1.72 and a beta of 0.43. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the business earned $3.42 earnings per share. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.80%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 63.97%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BDX. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James lowered their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.